Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357347 | 0.72 | IRAK4 (1.00) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL10254362 | 0.64 | IRAK4 (0.51) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL1748737 | 0.61 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL187054 | 0.60 | TLR8 (0.55) | IRAK4TLR8TLR7 | |
| SCHEMBL9736014 | 0.60 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL10254559 | 0.59 | IRAK4 (0.40) | IRAK4MAP3K7AURKAFLT3SYK | |
| SCHEMBL30039833 | 0.58 | ALDH1A1 (0.48) | — | |
| SCHEMBL187674 | 0.57 | MEN1 (0.52) | TLR8TLR7 | |
| SCHEMBL9984284 | 0.57 | TLR8 (0.43) | IRAK4TLR8TLR7KDREGFR | |
| SCHEMBL296605 | 0.56 | GPR84 (0.62) | TLR8TLR7KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885TLR8 45/4885TLR7 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.